TriSalus Life Sciences (NASDAQ:TLSI) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Several other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Lake Street Capital reduced their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $5.27 on Friday. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The stock has a market capitalization of $323.67 million, a PE ratio of -4.05 and a beta of 0.43. The firm has a 50 day moving average of $4.39 and a two-hundred day moving average of $4.31.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TLSI. First Light Asset Management LLC acquired a new stake in TriSalus Life Sciences during the 1st quarter worth $20,267,000. BlackRock Inc. acquired a new position in TriSalus Life Sciences in the second quarter valued at $12,099,000. Nantahala Capital Management LLC boosted its stake in TriSalus Life Sciences by 1.5% in the fourth quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after acquiring an additional 30,582 shares in the last quarter. Wasatch Advisors LP purchased a new position in shares of TriSalus Life Sciences during the first quarter worth about $5,752,000. Finally, Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after purchasing an additional 345,186 shares during the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.